Skip to main content
. 2021 Apr 20;12:615491. doi: 10.3389/fgene.2021.615491

TABLE 4.

CRISPR-Cas9 component format advantages, limits and advances.

Format Advantages Limitations Advances demonstrated in any species (rat in bold)
Cas9

Plasmid No limit on insert size Easy engineering High expression Delayed activity Mosaicism Increased off-targets Delayed activity Cas9 protein allowing rapid and more efficient editing (Kim et al., 2014; Ménoret et al., 2015) Large editing toolbox variants (Table 3) Improved chromatin accessibility (Chen F. et al., 2017; Ding et al., 2019) Cas9 engineered to activate repair pathways (Charpentier et al., 2018; Tran et al., 2019) Cas9 engineering to be degraded in G1 (Gutschner et al., 2016; Charpentier et al., 2018; Lomova et al., 2019)
mRNA Expression faster than plasmid Limit mosaicism and off-targets Delayed activity In vitro transcription efficiency/toxicity
Protein Ready to cut Limit mosaicism and off-targets Affordable and high quality Crystallization at high dose In vivo stability potentially immunogenic

gRNA

Plasmid No limit on insert size Easy to engineer Delayed activity Chemical modification (Kim S. et al., 2018; Filippova et al., 2019) Essential sequence, secondary structures and functional modules of gRNA (Briner et al., 2014; Kartje et al., 2018) Overlapping gRNA (Jang et al., 2018) gRNA engineering to activate repair pathways (Nakade et al., 2018; Tran et al., 2019)
IVT sgRNA Easy to produce and use Flexible in sequence and length Efficient Time-consuming production Induced immune responses Limited in chemical modification
Synthetic sgRNA Affordable and high quality Chemical modifications Ready to use Efficient Order full sgRNA for each project Long RNA synthesis Difficulties in adding fluorophore for tracking
Synthetic dgRNA Short RNA synthesis Low cost and high quality Same tracrRNA for all project Chemical modifications Fluorophores added for tracking Efficient crRNA & tracrRNA hybridization in vitro

DNA donor

ssODN Low cost synthesis High efficacy for mutation or short KI Limited in length to 200nt DNA synthesis progresses (Hao et al., 2020) Chemical modification (Renaud et al., 2016; Liang X. et al., 2017; Yu et al., 2020) Insertion close to cut site (Inui et al., 2014; Liang X. et al., 2017) 3′ overhang DNA donor (Liang X. et al., 2017; Hirotsune et al., 2020) Carry to cut site by Cas9 (Ma et al., 2017; Aird et al., 2018; Gu et al., 2018; Ling et al., 2020; Wang Z. et al., 2020) Carry to cut site by gRNA (Carlson-Stevermer et al., 2017; Lee et al., 2017) Carry to cut site by DNA donor engineering (Nguyen et al., 2020) DNA donor in vivo excision from plasmid (Aida et al., 2016; Yao et al., 2017; Zhang et al., 2017)
lsDNA Usable for long KI Limited in length Difficult to produce Mutated KI Expensive to synthesize
dsDNA Usable for long KI Easy to produce and engineer No limit on insert size Few random insertions
Plasmid Usable for long KI Easy to produce and engineer No limit on insert size Few random insertions

IVT, in vitro–transcribed; gRNA, guide RNA; sgRNA, single gRNA; dgRNA, dual gRNA; ssODN, single-stranded oligonucleotides; lsDNA, long single-stranded DNA; dsDNA, linear double-stranded DNA.